Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Resovist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Resovist (BAY86-4884, SH U 555 A) | PROCEDURE | Single bolus injection, followed by MRI |
Inclusion Criteria: 1. Present with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment. There should not be more than five liver lesions on type visualized on CT. The patient should be in a condi...
Resovist is used for the identification of hepatic lesions in patients with hepatic neoplasms, which are tumors or abnormal growths in the liver. It is an investigational agent that has been studied in a clinical trial setting for this purpose.
Resovist is developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded under the ticker symbol BAYRY on the over-the-counter market.
Resovist is in Phase 3 of clinical development. It has completed a Phase 3 clinical trial, but it is still considered investigational and has not been approved by regulatory authorities.
Resovist has been studied in one completed Phase 3 clinical trial with the identifier NCT00307866, titled 'Identification of Hepatic Lesions.' This trial enrolled 218 participants with hepatic neoplasms and was conducted in Italy.
Resovist is not FDA approved. It is an investigational agent that has completed a Phase 3 clinical trial, but it remains in clinical development and has not received approval from the U.S. Food and Drug Administration or other regulatory bodies.